Lead program SN101, a first-in-class non-opioid iPSC-derived therapy for chronic joint pain, moves toward IND-enabling ...
New ISSCA curriculum covers multiple adjunctive technologies used in longevity-focused practices and is intended to ...
In addition to the financing, Zenflow announced it has entered into an exclusive U.S. distribution agreement with Cook ...
New non-human primate data show Coave's ligand-conjugated suprachoroidal vector, coAAV-SCS, achieved up to 120-fold higher ...
Texas Ibogaine Research Corporation (“TIRC”), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing ...
Inducement Plan. Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious ...
Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development. TORONTO ...
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, ...
Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under ...
The study enrolled 143 patients across 10 U.S. sites and found that adding Symphony to standard of care significantly ...
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik ...
Evident announced today that it has completed the acquisition of CrestOptics S.p.A., a Rome-based developer and manufacturer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results